Analysts Are Neutral on Top Healthcare Stocks: DaVita (DVA), Exelixis (EXEL)


Analysts Are Neutral on Top Healthcare Stocks: DaVita (DVA), Exelixis (EXEL)

In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on DaVita, with a price target of $169.00. The company's shares closed last Friday at $157.42.

According to TipRanks.com, CFA has 0 stars on 0-5 stars ranking scale with an average return of

DaVita has an analyst consensus of Hold, with a price target consensus of $172.67, a 12.1% upside from current levels. In a report issued on February 14, Truist Financial also maintained a Hold rating on the stock.

According to TipRanks.com, Lawson has 0 stars on 0-5 stars ranking scale with an average return of

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $37.47 average price target, implying a 9.0% upside from current levels. In a report issued on February 11, BMO Capital also maintained a Hold rating on the stock with a $40.00 price target.

According to TipRanks.com, Sergott has currently 0 stars on a ranking scale of 0-5 stars, with an average return of

The word on The Street in general, suggests a Hold analyst consensus rating for Charles River Labs with a $183.00 average price target, implying a 18.0% upside from current levels. In a report issued on February 4, Evercore ISI also maintained a Hold rating on the stock with a $195.00 price target.

Previous articleNext article

POPULAR CATEGORY

corporate

12286

tech

11464

entertainment

15252

research

7035

misc

16117

wellness

12376

athletics

16146